
Opinion|Videos|November 20, 2024
Optimizing Regimens and Managing Adverse Events in TIE NDMM
Elizabeth O’Donnell, MD, comments on specific patient subgroups, such as frail or high-risk individuals, who benefit most from particular regimens. She discusses adverse events observed in combination therapies for transplant-ineligible patients with newly diagnosed multiple myeloma and shares her approaches to managing these adverse effects in clinical practice.
Advertisement
Episodes in this series

- Please comment on whether there are specific patient subgroups (eg, frail or high risk) that benefit most from one regimen over the other?
- Please comment on some adverse events observed in combination therapies in transplant-ineligible patients with newly diagnosed multiple myeloma.
- Please address how you manage these adverse effects in clinical practice.
Advertisement
Related to this article

An exploratory analysis of the phase 3 KEYNOTE-B15 trial found that ctDNA status was strongly prognostic for event-free survival regardless of treatment arm.

The KEYNOTE-866 trial did not meet its EFS primary end point with perioperative pembrolizumab added to neoadjuvant cisplatin and gemcitabine.

The sacituzumab govitecan, enfortumab vedotin, and zimberelimab triplet produced early, durable responses in untreated metastatic urothelial cancer.

Surufatinib plus serplulimab and cisplatin/etoposide produced a 69.8% ORR in advanced extrapulmonary neuroendocrine carcinoma.

Efficacy outcomes in KEYNOTE-905 were consistent with a contribution of both enfortumab vedotin and pembrolizumab in cisplatin-ineligible MIBC.

Patient-reported outcomes from the phase 3 lidERA trial show preserved functioning and less frequent joint pain with giredestrant vs standard endocrine therapy.

Arcotatug tavatecan improved PFS and OS vs physician’s choice in previously treated, CLDN18.2-positive advanced gastric and GEJ cancer.
Advertisement
Advertisement
Trending on OncLive
1
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
2
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
3
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
4
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
5


